Invitation for presentation of Sedana Medical’s interim report for the second quarter 2021
Sedana Medical AB will present its interim report for the second quarter 2021 in an audiocast on August 19 at 13.30 CEST.
According to the financial calendar, Sedana Medical plans to publish the report for the second quarter 2021 on Thursday August 19 at approximately 07.00 CEST. Sedana Medical hereby invites to a presentation of the report on the same day, where the interim CEO Jens Lindberg will present the report in English together with Peter Sackey CMO and Susanne Andersson CFO as well as answer questions.
Date: Thursday August 19th 2021
Time (CEST): 13.30
Link to audiocast: https://financialhearings.com/event/13794
Welcome!
For additional information, please contact:
Jens Lindberg, Interim President and CEO, +46 72 531 11 17
Susanne Andersson, CFO, +46 73 066 89 04
ir@sedanamedical.com
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device AnaConDa and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.